267 related articles for article (PubMed ID: 25546733)
1. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
[TBL] [Abstract][Full Text] [Related]
2. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
3. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
[TBL] [Abstract][Full Text] [Related]
4. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
[TBL] [Abstract][Full Text] [Related]
5. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
van den Heuvel-Eibrink MM; van Tinteren H; Bergeron C; Coulomb-L'Hermine A; de Camargo B; Leuschner I; Sandstedt B; Acha T; Godzinski J; Oldenburger F; Gooskens SL; de Kraker J; Vujanic GM; Pritchard-Jones K; Graf N
Eur J Cancer; 2015 Mar; 51(4):498-506. PubMed ID: 25592561
[TBL] [Abstract][Full Text] [Related]
6. Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.
Metzger ML; Stewart CF; Freeman BB; Billups CA; Hoffer FA; Wu J; Coppes MJ; Grant R; Chintagumpala M; Mullen EA; Alvarado C; Daw NC; Dome JS
J Clin Oncol; 2007 Jul; 25(21):3130-6. PubMed ID: 17634492
[TBL] [Abstract][Full Text] [Related]
7. A 23-year experience with malignant renal tumors in infancy and childhood.
Tröbs RB; Hänsel M; Friedrich T; Bennek J
Eur J Pediatr Surg; 2001 Apr; 11(2):92-8. PubMed ID: 11371043
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30-year SIOP-RTSG experience.
Hol JA; Jongmans MCJ; Sudour-Bonnange H; Ramírez-Villar GL; Chowdhury T; Rechnitzer C; Pal N; Schleiermacher G; Karow A; Kuiper RP; de Camargo B; Avcin S; Redzic D; Wachtel A; Segers H; Vujanic GM; van Tinteren H; Bergeron C; Pritchard-Jones K; Graf N; van den Heuvel-Eibrink MM;
Cancer; 2021 Feb; 127(4):628-638. PubMed ID: 33146894
[TBL] [Abstract][Full Text] [Related]
10. Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
; van den Heuvel-Eibrink MM; Pritchard-Jones K; van Tinteren H; Graf N
Eur J Cancer; 2015 May; 51(8):995-6. PubMed ID: 25840668
[No Abstract] [Full Text] [Related]
11. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
12. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
[TBL] [Abstract][Full Text] [Related]
13. Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial.
de Kraker J; Graf N; van Tinteren H; Pein F; Sandstedt B; Godzinski J; Tournade MF;
Lancet; 2004 Oct 2-8; 364(9441):1229-35. PubMed ID: 15464183
[TBL] [Abstract][Full Text] [Related]
14. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
[TBL] [Abstract][Full Text] [Related]
15. Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols.
Groenendijk A; van Tinteren H; Jiang Y; de Krijger RR; Vujanic GM; Godzinski J; Rübe C; Schenk JP; Morosi C; Pritchard-Jones K; Al-Saadi R; Vaidya SJ; Verschuur AC; Ramírez-Villar GL; Graf N; de Camargo B; Drost J; Perotti D; van den Heuvel-Eibrink MM; Brok J; Spreafico F; Mavinkurve-Groothuis AMC
Eur J Cancer; 2022 Mar; 163():88-97. PubMed ID: 35042071
[TBL] [Abstract][Full Text] [Related]
16. Age is not a prognostic factor in children with Wilms tumor beyond stage I in Africa.
Aronson DC; Hadley GP
Pediatr Blood Cancer; 2014 Jun; 61(6):987-9. PubMed ID: 24453084
[TBL] [Abstract][Full Text] [Related]
17. Update on relapses in unilateral nephroblastoma registered in 3 consecutive SIOP/GPOH studies - a report from the GPOH-nephroblastoma study group.
Furtwängler R; Nourkami N; Alkassar M; von Schweinitz D; Schenk JP; Rübe C; Siemer S; Leuschner I; Graf N
Klin Padiatr; 2011 May; 223(3):113-9. PubMed ID: 21509706
[TBL] [Abstract][Full Text] [Related]
18. Results of Wilms' tumour management in two tertiary-care hospitals in Asia.
Sen S; Kadamba P; Al-AbdulAaly M; Mammen KE; Ahmed S
Pediatr Surg Int; 1998 Jan; 13(1):42-4. PubMed ID: 9391203
[TBL] [Abstract][Full Text] [Related]
19. Repeat nephron-sparing surgery for children with bilateral Wilms tumor.
Kieran K; Williams MA; McGregor LM; Dome JS; Krasin MJ; Davidoff AM
J Pediatr Surg; 2014 Jan; 49(1):149-53. PubMed ID: 24439600
[TBL] [Abstract][Full Text] [Related]
20. High dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study.
Hempel L; Kremens B; Weirich A; Graf N; Zintl F; Ludwig R
Klin Padiatr; 1996; 208(4):186-9. PubMed ID: 8776705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
